ABSTRACT
INTRODUCTION
Screening for toxoplasmosis is not mandatory in Italy, but National Health Service reimbursement is provided for one test before pregnancy to assess immune status and a monthly follow-up for seronegative women, as well as after confirmed acute infection (DPR 245 10/09/98). Seroprevalence for Toxoplasma gondii antibodies has dramatically decreased in the last decades in Italy as well as in many other European Countries.
1 In our region it was 48% in 1981, 2 and now has dropped to 22% for Italian women and 33% for immigrants. 3 Though screening is not mandatory, risk awareness causes almost 85% of pregnant women to be tested for the first time during the first trimester of pregnancy. Conversely, only few women are tested for Toxoplasma antibodies before becoming pregnant, usually only in cases of in vitro fertilization. In addition, most seronegative women undergo serological tests about three times during pregnancy, with a significant difference in number of sampling between Italian and immigrant women.
3 At the start of the screening program, 1.7% of women were positive for IgM, and were therefore referred as outpatients to the Infectious Disease Clinic, IRCCS San Matteo Hospital Foundation, Pavia, Italy, for further investigation. Our experience as a reference laboratory from January to December 2007 is described here.
METHODS
The study included all pregnant women with suspected toxoplasmosis acquired during pregnancy referred to the Infectious Disease Clinic, IRCCS San Matteo Hospital Foundation, Pavia, Italy, for further investigation.
At All newborns were followed up to one year of age in order to exclude or confirm the diagnosis of congenital toxoplasmosis. 4 All pregnant women with acute and undetermined stages of infection in the second trimester were treated with pyrimethamine, sulfadiazine and folinic acid. 
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RESULTS
In the course of 2007, 236 women with suspected acute (IgM positive) Toxoplasma infection were followed up in the reference laboratory. Thirty five (15%) were tested before pregnancy, 134 (57%) during the first trimester of pregnancy, 45 (19%) during the second trimester, and 22 (9%) during the third trimester.
In the reference laboratory, 91 women had test results indicating acute toxoplasmosis, and 10 had undetermined status of infection. These 101 patients represented 42.8% of the 236 women referred. Acute toxoplasmosis could be excluded in the remaining 135 patients, of whom 53 were non-immune (Table 1) . Of the 35 women tested before pregnancy, 14 resulted non-immune, 11 immune, and 10 with acute infection (Table 1) .
Of 134 sera collected from women in the first trimester of pregnancy, 19 resulted non-immune, 71 with past infection, and 44 with acute infection (Table 1) . Twenty nine sera were negative for IgG and positive for IgM, but of these, only 10 patients had true seroconversion (positive IgM antibodies confirmed with IgM ISAGA test and/or with type II Western Blot, as defined in Methods). In these 10 cases IgG appeared, even if its production was delayed and lowered by therapy, as described elsewhere. 5 In 105 sera positive for IgG and IgM, acute infection was ruled out on the basis of high IgG avidity index in 71 women. All women with acute infection were treated with spiramycin and 31 underwent prenatal diagnosis with negative results. No infected newborns were observed in this group.
Forty-five women were tested for the first time in the second trimester of pregnancy, of whom 11 resulted non-immune, 25 with acute infection, and 9 with undetermined status (Table 1) . Twenty-three scored negative for IgG and positive for IgM, of whom 12 had confirmed seroconversion (as defined above), and in 11 patients the infection was excluded because of a negative IgM ISAGA test and a negative type II IgG/IgM Western Blot. In all these 11 cases, after therapy discontinuation, no specific IgG appeared. In 13 women, sera scored positive for IgG and IgM with low IgG avidity index. Although a low avidity index is not always related to an acute infection (sometimes the avidity index remains persistently low), we could not exclude acute infection during pregnancy, so we treated and followed up these patients like we did with acute infections. 6 Hence, the possibility of infection occurred during pregnancy was considered in 25 cases, and infection status was undetermined in nine cases that came to our laboratory too late during pregnancy. Nine women underwent prenatal diagnosis and all scored negative. No infected newborns were observed.
Twenty-two women with suspected acute infection were tested for the first time during the third trimester of pregnancy. In the reference laboratory, acute infection was considered in 12 patients, of whom 11 patients were defined as having seroconversion during pregnancy and one woman with low avidity index was treated and followed up as an acute case. In this group we observed one case of undetermined stage of infection (IgG and IgM positive, high IgG index) and 10 negative women. All acute and undetermined stages of infection were treated with pyrimethamine and sulfadiazine. Three infected newborns were observed In this group. (Table 1) The only newborn that showed severe signs of disease was born from an immigrant mother never tested before the 28th week of pregnancy. This woman was addressed to our laboratory when ultrasound abnormalities (hydrocephalus, cerebral calcifications) suggested Toxoplasma infection. High IgG titres and IgM and IgA positive results confirmed the diagnosis of maternal toxoplasmosis, even if IgG avidity index was already high. We could not define the gestational age at which seroconversion occurred and classified this infection as undetermined. The woman had not received therapy until diagnosis was established in our laboratory.
DISCUSSION
Seroprevalence data in pregnant women of our region showed a decrease during the last 30 years like in many other European Countries.
1 This fact may be due to a change in dietary habits, although seroprevalence in transplant recipients is higher (about 50%, Meroni V, unpublished data). Nevertheless, infection may still occur.
All women should be tested before pregnancy to evaluate their immunological status regarding toxoplasmosis, and should receive counselling on toxoplasmosis in pregnancy. Screening system in Italy is efficient in recruiting women in the first trimester of pregnancy, but we need to increase the use of preconceptional screening. Women should be encouraged to perform tests for toxoplasmosis before and during early pregnancy. This screening must be consistently based on specific IgG and IgM detection, and cases suspected of acute toxoplasmosis should be referred to a reference laboratory. This allows to reassure immune women and to avoid unnecessary treatment and follow up of pregnant women and their newborns.
All women were referred to our laboratory for the presence of anti-Toxoplasma IgM antibodies. The presence of anti-Toxoplasma IgM, however, is not synonymous with acute infection. The use of different tests, that only a reference laboratory can perform, allowed us to exclude acute infection in many cases. These tests have different specificity and sensitivity and were useful to date the infection. For instance, Liaison Toxo IgG is more sensitive and could detect serocoversion earlier than VIDAS Toxo IgG II. IgM ISAGA is more specific than Liaison IgM but could detect anti-Toxoplasma IgM too long. IgG/IgM Western Blot II is very specific because employs only purified antigens recognized by the specific antibodies at the beginning of infection.
